Close Menu

NEW YORK (GenomeWeb) – Albany Molecular Research (AMRI) announced it has obtained a non-exclusive license for CRISPR/Cas9 technology from the Broad Institute.

The contract research organization said in a statement that CRISPR offered "significant utility" for pharmaceutical research and development, especially drug target assessment, in vitro model development, and optimization. AMRI reported that it has already used CRISPR/Cas9 in both customer and internal R&D projects.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.

A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.

Broad Institute researchers describe an approach they've dubbed "DNA microscopy."

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.